DiagnosTear Signs Letter of Intent to Advance Commercial Expansion of TeaRx(TM) in India
Vancouver, British Columbia--(Newsfile Corp. - January 22, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), an innovator in point-of-care ocular diagnostics, today announced the signing of a Letter of Intent (LOI) with Renovate Biologicals Pvt. Ltd. ("Renovate"), a Hyderabad-based distribution company active in the ophthalmic market, to support the commercial evaluation and potential distribution of TeaRx™ in India. The LOI is part of DiagnosTear's...
2026-01-22 5:00 PM EST
DiagnosTear Announces Interim Clinical Results Indicating High Efficiency from TeaRx(TM) Red Eye
Vancouver, British Columbia--(Newsfile Corp. - January 16, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a fast-growing innovator in point-of-care ocular diagnostics, today announced highly encouraging interim results from its ongoing multi-center Israeli clinical study supporting the development of its TeaRx™ Red Eye diagnostic platform. TeaRx™ Red Eye is being developed as the first rapid, multi-biomarker, point-of-care diagnostic device...
2026-01-16 7:00 PM EST
DiagnosTear Signs Non-Binding Term Sheet with Sheba Impact and Ramot to Exclusively License New Eye Imaging Technology, CLARIFY, Enabling Needle-Free Blood Count
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a leader in rapid eye based diagnostic technologies, is pleased to announce that the Company has signed a non-binding term sheet with Sheba Impact, the Technology Transfer office ("TTO") of Sheba Medical Center ("Sheba MC"), Israel's largest hospital and one of the world's most innovative clinical research institutions, and with Ramot, the...
2025-12-17 6:00 PM EST
DiagnosTear Technologies Inc. - Confirmation of No Material Change
Vancouver, British Columbia--(Newsfile Corp. - December 9, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a fast-growing innovator in point-of-care ocular diagnostics, at the request of CIRO, wishes to confirm that the Company's management is unaware of any material change in the Company's operations that would account for the recent increase in market activity. About DiagnosTear Technologies Inc. DiagnosTear Technologies Inc. is a global leader...
2025-12-09 1:19 PM EST
DiagnosTear Announces Clinical Study with AlyaTec to Advance Analytical Validation and FDA Submission Pathway of TeaRx(TM) Red Eye Diagnostic Test
Vancouver, British Columbia--(Newsfile Corp. - December 2, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a fast-growing innovator in point-of-care ocular diagnostics, is pleased to announce a collaboration with AlyaTec, a globally renowned Contract Research Organization (CRO), specializing in allergy and environmental diseases, to initiate a clinical study of TeaRx™ Red Eye in order to advance the global commercialization of TeaRx™ Red Eye and...
2025-12-02 5:00 PM EST
DiagnosTear Technologies Announces Initiation of a Collaboration with LV Prasad Eye Institute for Advancing the Clinical Validation of TeaRx(TM) Red Eye Diagnostic Test
Vancouver, British Columbia--(Newsfile Corp. - November 26, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) ("DiagnosTear" or the "Company"), a leader in developing cutting-edge point-of-care eye diagnostic solutions, is pleased to announce its scientific collaboration with the renowned LV Prasad Eye Institute (LVPEI) in Hyderabad, India. The partnership supports the clinical validation of TeaRx™, the Company's next-generation Red Eye diagnostic test. DiagnosTear is currently developing a...
2025-11-26 4:15 PM EST
DiagnosTear Technologies Inc. Announces Closing of Private Placement of Units
Vancouver, British Columbia--(Newsfile Corp. - November 18, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company") Further to its press release from June 3, 2025 and October 24, 2025, the Company is pleased to announce that it has closed its non-brokered private placement of units ("Units") with each Unit consisting of one common share in the capital of the Company (each a "Share") and one common share purchase warrant (each a "Warrant"), in the principal...
2025-11-18 8:30 AM EST
DiagnosTear Technologies Inc. Announces Upsizing of Private Placement of Units
Vancouver, British Columbia--(Newsfile Corp. - October 24, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company") is pleased to announce, further to its press release from June 3, 2025, its previously announced non-brokered private placement of units ("Units") at a price of $0.50 per Unit has been increased to up to 2,000,000 units for aggregate gross proceeds of $1,000,000 (the "Offering"). Each Unit will consist of one common share of the Company (a...
2025-10-24 8:37 AM EDT
DiagnosTear Announces Frankfurt Stock Exchange Listing and Corporate Awareness Agreement
Vancouver, British Columbia--(Newsfile Corp. - October 22, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company") is pleased to announce that its common shares are now listed and trading on the Frankfurt Stock Exchange under the trading symbol "X8F." The Company is also pleased to announce it has retained bullVestor Medien GmbH ("bullVestor") to provide certain marketing services for a period of 6 months, commencing on October 21, 2025. This news release...
2025-10-22 8:35 AM EDT